Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:IVVD NASDAQ:LSB NASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.99+5.9%$1.68$0.95▼$3.19$71.54M0.1281,917 shs599,362 shsIVVDInvivyd$0.97-1.7%$0.74$0.35▼$2.74$116.90M0.518.12 million shs3.97 million shsLSBLakeShore Biopharma$0.83+3.3%$0.94$0.59▼$8.60$17.15M0.56126,711 shs8,881 shsRPTXRepare Therapeutics$1.67+0.6%$1.51$0.89▼$4.07$71.74M0.93299,185 shs48,875 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics+1.08%+3.87%+19.75%+5.92%+41.35%IVVDInvivyd+13.79%+87.54%+22.75%+4.24%+10.00%LSBLakeShore Biopharma+0.63%-4.31%-11.16%-25.23%-81.90%RPTXRepare Therapeutics+0.61%+7.10%+8.50%+19.42%-45.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics2.1696 of 5 stars3.53.00.00.02.30.00.6IVVDInvivyd4.0365 of 5 stars3.65.00.00.03.34.20.6LSBLakeShore Biopharma1.1611 of 5 stars0.05.00.00.02.20.80.6RPTXRepare Therapeutics2.8239 of 5 stars3.33.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.00Buy$7.80291.96% UpsideIVVDInvivyd 3.25Buy$3.18227.17% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/ARPTXRepare Therapeutics 2.50Moderate Buy$4.50169.46% UpsideCurrent Analyst Ratings BreakdownLatest LSB, RPTX, IVVD, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $3.008/13/2025GANXGain TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.007/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/26/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain TherapeuticsN/AN/AN/AN/A$0.10 per shareN/AIVVDInvivyd$25.38M4.61N/AN/A$0.36 per share2.70LSBLakeShore Biopharma$614.96M0.03N/AN/A$3.35 per share0.25RPTXRepare Therapeutics$250K286.97N/AN/A$2.57 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A8.85N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)LSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/AN/ARPTXRepare Therapeutics-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%11/6/2025 (Estimated)Latest LSB, RPTX, IVVD, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/A8/8/2025Q2 2025RPTXRepare Therapeutics-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.091.791.79IVVDInvivydN/A1.331.33LSBLakeShore Biopharma0.051.020.75RPTXRepare TherapeuticsN/A6.306.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%IVVDInvivyd70.36%LSBLakeShore Biopharma52.64%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics7.18%IVVDInvivyd25.40%LSBLakeShore BiopharmaN/ARPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableIVVDInvivyd100120.14 million89.63 millionOptionableLSBLakeShore Biopharma77320.77 millionN/AN/ARPTXRepare Therapeutics18042.96 million38.02 millionOptionableLSB, RPTX, IVVD, and GANX HeadlinesRecent News About These CompaniesRepare Therapeutics Announces Licensing Deal and Strategic UpdatesAugust 12, 2025 | theglobeandmail.comRepare Therapeutics (NASDAQ:RPTX) Posts Earnings ResultsAugust 11, 2025 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street ZenAugust 10, 2025 | marketbeat.comRepare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2025 | zacks.comRepare (RPTX) Q2 Loss Narrows 52%August 8, 2025 | fool.comRepare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | financialpost.comFRepare Therapeutics (RPTX) to Release Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comRepare Therapeutics Jumps 15% After $10M Licensing Deal With DebiopharmJuly 18, 2025 | uk.finance.yahoo.comRepare Therapeutics Inc. (RPTX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comRepare inks licensing deal with Debiopharm for lunresertibJuly 16, 2025 | thepharmaletter.comTRepare finds suitor for paused PKMYT1 inhibitor in current partner DebiopharmJuly 16, 2025 | fiercebiotech.comFRepare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush InJuly 16, 2025 | msn.comRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | businesswire.comRepare Therapeutics Inc (RPTX) - Investing.comJuly 3, 2025 | investing.comRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30, 2025 | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSB, RPTX, IVVD, and GANX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.99 +0.11 (+5.85%) Closing price 04:00 PM EasternExtended Trading$1.99 0.00 (0.00%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Invivyd NASDAQ:IVVD$0.97 -0.02 (-1.72%) Closing price 04:00 PM EasternExtended Trading$0.96 -0.01 (-0.82%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.LakeShore Biopharma NASDAQ:LSB$0.83 +0.03 (+3.25%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Repare Therapeutics NASDAQ:RPTX$1.67 +0.01 (+0.60%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.02 (-1.20%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access